FoundMyFitness · 2022-03-09 · Rhonda Patrick (host), Peter Diamandis, Tony Robbins

Peter Diamandis and Tony Robbins on strategies that promote longevity now – and in the near future

52 research-tied claims examined: 3 contradicted 7 overstated 12 context 18 supported 12 unverified

Contradicted by research

0:09:06 Peter Diamandiscontradictedmoderate

Placental stem cells have not been thymized and do not provoke an immune reaction when administered to any recipient.

"Another thing is that the cells from the placenta haven't developed—they haven't been thymized yet. They haven't developed an "us versus them" characteristic, so you can give placental cells to anybody, because the placenta doesn't generate an immune reaction against cells and your cells don't generate an immune reaction against placental cells." (said at 0:09:06)

The claim is contradicted on multiple biological and immunological grounds. First, 'thymization' (thymic education and selection) is a process specific to T lymphocytes, not stem cells or stromal cells. Second, while placental-derived stem cells and mesenchymal stromal cells (MSCs) possess immunomodulatory and hypoimmunogenic properties (such as lower baseline HLA expression), they are immune-evasive rather than completely immune-privileged. Published evidence demonstrates that allogeneic placental and mesenchymal cells can elicit host alloimmune responses, induce donor-specific anti-HLA antibodies, and undergo immune clearance/rejection upon administration to immunocompetent recipients.

contradicts: Mesenchymal stem cells: immune evasive, not immune privileged. (Nature biotechnology 2014) · cited 1567x in the literature
"MSCs have long been reported to be hypoimmunogenic or 'immune privileged'... However, recent studies describing generation of antibodies against and immune rejection of allogeneic donor MSCs suggest that MSCs may not actually be immune privileged." (abstract, results)
pubmed full study (doi)
contradicts: Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in alloge… (Stem cells and development 2015) · cited 22x in the literature
"After two infusions of DSCs, the JEB patient had developed multispecific anti-HLA class-I antibodies... AM and DSC infusions may have improved the healing process in the JEB patient, but DSCs appeared to induce anti-HLA antibodies." (abstract, results)
pubmed full study (doi)
context: Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenc… (International journal of molecular sciences 2021) · cited 33x in the literature
"The low expression of HLA class I and II on f-hPSCs reduces the risk of rejection in allogeneic or xenogeneic applications in normal immunocompetent hosts." (abstract, results, passage verified)
pubmed full study (doi)

0:10:17 Tony Robbinscontradictedhigh

Biosplice's osteoarthritis treatment is a single injection that regrows all tendons in 11 months to the state of 16-year-old tendons.

"And so the one they're getting approval for first is for osteoarthritis. It's a single injection, and in 11 months you regrow all your tendons, but based on the boot disk as what's just described, they're like 16-year-old tendons, even if you're 40, 50, 60, or 70 years old." (said at 0:10:17)

Biosplice Therapeutics developed lorecivivint (SM04690), an intra-articular CLK/DYRK and Wnt pathway inhibitor, as an investigational disease-modifying drug targeting cartilage and inflammation in knee osteoarthritis—not tendon regeneration. In Phase 3 randomized controlled trials (such as OA-10 and OA-11) and systematic meta-analyses, a single injection of lorecivivint failed to meet primary endpoints for pain reduction and did not demonstrate significant structural regeneration or joint space improvement compared to placebo. There is no clinical evidence that lorecivivint regrows tendons or restores joint tissues to an adolescent state.

contradicts: A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising p… (Clinical and experimental rheumatology 2025) · cited 2x in the literature
"No discernable treatment effects of LOR compared with PBO were revealed by the analysis of other endpoints. Neither treatment group showed meaningful medial JSW loss over 52 weeks." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10… (Clinical and experimental rheumatology 2025) · cited 4x in the literature
"In the full analysis set (FAS), LOR failed to meet the primary endpoint when compared to PBO. No significant treatment differences were noted in other efficacy endpoints." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Efficacy and safety of lorecivivint for the treatment of knee osteoarthritis: A systematic… (Journal of orthopaedic surgery (Hong Kong) 2026)
"However, it did not significantly improve functional outcomes, Pain Numeric Rating Scale scores, patient global assessment, or structural changes at the assessed time points." (abstract, results, passage verified)
pubmed full study (doi)

0:23:29 Tony Robbinscontradictedhigh

Coronary artery calcification (a high calcium score) represents stabilized plaque unlikely to rupture, whereas soft plaque is the primary driver of acute arterial blockage and heart attacks.

"Well, that's okay because a high calcium score means that the plaque in your coronary arteries have been calcified and they're unlikely to rupture. What really is a concern is soft plaque. And uh you've seen people with a zero calcium score having a heart attack where the plaque inside of the coronary arteries uh can rupture and then go and block the coronary artery, starve it from oxygen, your heart from oxygen, give you a heart attack." (said at 0:23:29)

The speaker claims that having a high coronary artery calcium (CAC) score is benign ("that's okay") because calcified plaques are stabilized and unlikely to rupture, and emphasizes soft plaque in individuals with a score of zero. This directly contradicts extensive prospective cardiovascular evidence. While dense focal calcification within a single plaque can alter local mechanical stress, a high CAC score reflects a large overall burden of coronary atherosclerosis (including extensive soft and mixed plaque) and is one of the strongest independent predictors of acute myocardial infarction and cardiac death. In landmark prospective cohort data from the Multi-Ethnic Study of Atherosclerosis (MESA), participants with CAC scores above 300 had a nearly tenfold higher risk of coronary events compared to those with a score of zero (hazard ratio 9.67). Conversely, a CAC score of zero is associated with an exceptionally low short- and intermediate-term event rate, rather than being the primary scenario for heart attacks.

contradicts: Coronary calcium as a predictor of coronary events in four racial or ethnic groups. (The New England journal of medicine 2008) · cited 2984x in the literature
"In comparison with participants with no coronary calcium, the adjusted risk of a coronary event was increased by a factor of 7.73 among participants with coronary calcium scores between 101 and 300 and by a factor of 9.67 among participants with scores above 300 (P<0.001 for both comparisons)." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Role of Coronary Artery Calcium Score CT in Risk Stratification of Asymptomatic Individual… (Journal of cardiovascular development and disease 2025) · cited 4x in the literature
"CACS reliably identifies subclinical atherosclerosis and stratifies cardiovascular risk in asymptomatic individuals. Large studies, including the Multi-Ethnic Study of Atherosclerosis (MESA), demonstrate that CACS predicts 10-year cardiovascular events, improves risk reclassification beyond traditional scores, and identifies very low-risk individuals (those with a CAC of 0)." (abstract, results, passage verified)
pubmed full study (doi)

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.